Recruiting

Genetic Screening

Sponsor:

Abramson Cancer Center at Penn Medicine

Code:

NCT02478892

Conditions

Pancreatic Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen

Blood sample collection for research

Study Details

Brief summary:

The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.

Conditions

Pancreatic Cancer

Study ID

NCT02478892

Start date

May, 2015

Status verified date

Feb, 2026

Completion date

May, 2030

Anticipated

Primary completion date

May, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria

  • Age >= 18
  • Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation
  • If no history of PDAC in a first or second degree relative, age >= 50
  • If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer

Exclusion Criteria

• Pregnancy

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Interventions

Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen

Participants in this study should be undergoing pancreatic cancer screening with endoscopic ultrasound or MRI as part of their standard care. These should typically be done at least every 12 months, and the imaging tests will be ordered as routine clinical tests and will be billed to the participant's insurance. This study does not cover the costs of these screening tests, however the study will track the results of these screening tests.

Blood sample collection for research

Up to 40mL of blood may be collected for analysis at each screening examination.

Primary outcome measure

  • identifying pancreatic neoplastic lesions lesions in patients with BRCA1/2 mutations and other less common, but related mutations (ATM, PALB2) as well as mutations identified in the future. [ Time Frame: 10 years ]

Central Contacts and Locations

Central contacts

Bryson Katona, MD

Bryson.Katona@pennmedicine.upenn.edu

Locations

Abramson Cancer Center of the University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19004

Contacts

Bryson Katona, MD

855-216-0098Bryson.Katona@pennmedicine.upenn.edu

Principal Investigator:

Bryson Katona, MD

More Information

Sponsor

Abramson Cancer Center at Penn Medicine

Last update posted

Feb 5, 2026

Last verified

Feb, 2026

Keywords

  • high risk
  • specifically those with BRCA1/2 mutations

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2026-02-05.